阿帕替尼联合卡瑞利珠单抗对中晚期非小细胞肺癌患者血清肿瘤标志物及不良反应的影响

Effects of apatinib combined with carrilizumab on serum tumor markers and adverse reactions in patients with advanced non-small cell lung cancer

目的观察阿帕替尼联合卡瑞利珠单抗对中晚期非小细胞肺癌患者血清肿瘤标志物及不良反应的影响。方法回顾性选取2022年1月—2024年1月福建省肿瘤医院收治的中晚期非小细胞肺癌患者40例,根据治疗方案不同分为阿帕替尼联合组和卡瑞利珠单抗组,每组20例。卡瑞利珠单抗组给予卡瑞利珠单抗治疗,阿帕替尼联合组给予阿帕替尼联合卡瑞利珠单抗治疗,21 d为1个周期,治疗3个周期。比较2组治疗前后血清肿瘤标志物[细胞角蛋白19片段抗原(CYFRA21-1)、癌胚抗原(CEA)]水平、生活质量评分及不良反应。结果治疗3个周期后,2组血清CYFRA21-1及CEA水平均低于治疗前,且阿帕替尼联合组低于卡瑞利珠单抗组(P<0.05或P<0.01);2组生理领域、环境领域、社会领域及总主观感受评分均高于治疗前,且阿帕替尼联合组高于卡瑞利珠单抗组(P<0.01)。阿帕替尼联合组与卡瑞利珠单抗组各项不良反应发生率比较无显著差异(P>0.05)。结论阿帕替尼联合卡瑞利珠单抗治疗中晚期非小细胞肺癌可以稳定病情,改善生活质量,且不会增加药物不良反应,可见安全性较高。

Objective To observe the effects of apatinib combined with carrilizumab on serum tumor markers and adverse reactions in patients with advanced non-small cell lung cancer.Methods Forty patients with advanced non-small cell lung cancer admitted to Fujian Cancer Hospital from January 2022 to January 2024 were retrospectively selected,and divided into apatinib combination group and carrilizumab group according to different treatment regimen,with 20 cases in each group.The carrilizumab group was treated with carrilizumab,and the apatinib combined group was treated with apatinib combined with carrilizumab.Twenty-one days was 1 cycle,and 3 cycles were treated.The levels of serum tumor markers cytokeratin 19 fragment antigen(CYFRA21-1),carcinoembryonic antigen(CEA),quality of life score before and after treatment,and adverse reactions were compared between 2 groups.Results After 3 cycles of treatment,serum CYFRA21-1 and CEA levels in 2 groups were lower than before treatment,and apatinib combination group were lower than carrilizumab group(P<0.05 or P<0.01).The scores of physiological domain,environmental domain,social domain and total subjective perception in 2 groups were higher than before treatment,and apatinib combination group′s scores were higher than those of carrilizumab group(P<0.01).There was no significant difference in the incidence of adverse reactions between apatinib combination group and carrilizumab group(P>0.05).Conclusion Apatinib combined with carrilizumab in the treatment of advanced non-small cell lung cancer can stabilize the disease,improve the quality of life,and does not increase adverse drug reactions,with high safety.